DOR BIOPHARMA EXECUTES LETTER OF INTENT FOR ACQUISITION OF GASTROTECH PHARMA

A A

DOR BioPharma, Inc. (AMEX: DOR) ("DOR" or the "Company"), announced today that it has signed a binding letter of intent to acquire Gastrotech Pharma A/S ("Gastrotech"), a private Danish biotechnology company based in Copenhagen, Denmark. Gastrotech develops therapeutics based on peptide hormones to treat cancer and gastrointestinal (GI) diseases and conditions. Gastrotech was founded on technology developed at the Sahlgrenska University Hospital in Sweden which is known as the development cradle of Growth Hormone and IGF-1 research.
Genetic Engineering News